Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
DGX · NYSE · Healthcare
Fundamental quality
57
out of 100
Quest Diagnostics Inc earns a fundamental-quality score of 57 out of 100, profiling it as a company of reasonable quality. Its score rests mainly on its financial strength (net debt 2.27× EBITDA). Its weakest area is its growth (revenue +3.8%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Quest Diagnostics is the other half of America's clinical-lab duopoly: routine tests, advanced diagnostics and employer health programs. Its business is turning every blood tube into data, millions of times a day.
EPS growth: -1.9% · Revenue growth: 3.8%
Net margin: 9.2% · ROE: 14.1% · ROIC: 10%
Net debt/EBITDA: 2.27x · FCF: 11.7%
Source: SEC EDGAR · TTM through 30/06/2026
The score includes +1 for dividend strength: 7 consecutive years of increases. Keeping that streak demands growing cash generation and balance-sheet discipline.
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 9,437 | 1,431 | 1,587 | 2,857 |
| 2021 | 10,788 | 1,995 | 1,830 | 3,140 |
| 2022 | 9,883 | 946 | 1,314 | 3,665 |
| 2023 | 9,252 | 854 | 864 | 4,027 |
| 2024 | 9,872 | 871 | 909 | 5,668 |
| 2025 | 11,035 | 992 | 1,359 | 5,251 |
Between 2020 and 2025, revenue went from $9,437M to $11,035M (+17%) and net income went from $1,431M to $992M (-31%). Meanwhile, its margins have narrowed (from 15% to 9%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$1.8
per share, yearly
35.6% of earnings
Payout
7 straight years raising it
Growth
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Quest Diagnostics Inc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Quest Diagnostics Inc a good company to invest in?
In terms of business quality, Quest Diagnostics Inc scores 57 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Quest Diagnostics Inc a profitable company?
Quest Diagnostics Inc is profitable, with a net margin of 9.2%, though a thin one.
Does Quest Diagnostics Inc have a lot of debt?
A moderate level: its net debt is 2.27 times its EBITDA.
Is Quest Diagnostics Inc growing?
Its revenue has grown 3.8% annualized in recent years.
Does Quest Diagnostics Inc generate cash?
Yes. It converts about 11.7% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Amgen (AMGN) · Gilead Sciences (GILD) · Stryker (SYK) · Vertex Pharmaceuticals (VRTX) · Boston Scientific (BSX) · Medtronic (MDT) · see more →
The best Healthcare stocks by our model →
Compare Quest Diagnostics Inc with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Quest Diagnostics Inc's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.